Crenolanib

DB11832

small molecule investigational

Deskripsi

Crenolanib is under investigation for the treatment of Diffuse Intrinsic Pontine Glioma and Progressive or Refractory High-Grade Glioma.

Struktur Molekul 2D

Berat 443.551
Wujud -

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

66 Data
Acetaminophen The serum concentration of Acetaminophen can be increased when it is combined with Crenolanib.
Propacetamol The serum concentration of Propacetamol can be increased when it is combined with Crenolanib.
Salmon calcitonin The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Crenolanib.
Thyrotropin alfa The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Crenolanib.
Follitropin The therapeutic efficacy of Follitropin can be decreased when used in combination with Crenolanib.
Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Crenolanib.
Carbimazole The therapeutic efficacy of Carbimazole can be decreased when used in combination with Crenolanib.
Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Crenolanib.
Propylthiouracil The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Crenolanib.
Methimazole The therapeutic efficacy of Methimazole can be decreased when used in combination with Crenolanib.
Liotrix The therapeutic efficacy of Liotrix can be decreased when used in combination with Crenolanib.
3,5-Diiodotyrosine The therapeutic efficacy of 3,5-Diiodotyrosine can be decreased when used in combination with Crenolanib.
Tiratricol The therapeutic efficacy of Tiratricol can be decreased when used in combination with Crenolanib.
Parathyroid hormone The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Crenolanib.
Teriparatide The therapeutic efficacy of Teriparatide can be decreased when used in combination with Crenolanib.
Potassium Iodide The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Crenolanib.
Dibromotyrosine The therapeutic efficacy of Dibromotyrosine can be decreased when used in combination with Crenolanib.
Thyroid, porcine The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Crenolanib.
Potassium perchlorate The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Crenolanib.
Protirelin The therapeutic efficacy of Protirelin can be decreased when used in combination with Crenolanib.
3,5-diiodothyropropionic acid The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Crenolanib.
Methylthiouracil The therapeutic efficacy of Methylthiouracil can be decreased when used in combination with Crenolanib.
Elcatonin The therapeutic efficacy of Elcatonin can be decreased when used in combination with Crenolanib.
Benzylthiouracil The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Crenolanib.
Thyrotropin The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Crenolanib.
Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Crenolanib.
Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Crenolanib.
Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Crenolanib.
Methoxy polyethylene glycol-epoetin beta The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Crenolanib.
Lidocaine The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Lidocaine.
Ropivacaine The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Ropivacaine.
Bupivacaine The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Bupivacaine.
Cinchocaine The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Cinchocaine.
Dyclonine The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Dyclonine.
Procaine The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Procaine.
Prilocaine The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Prilocaine.
Proparacaine The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Proparacaine.
Meloxicam The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Meloxicam.
Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Oxybuprocaine.
Cocaine The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Cocaine.
Mepivacaine The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Mepivacaine.
Levobupivacaine The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Levobupivacaine.
Diphenhydramine The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Diphenhydramine.
Benzocaine The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Benzocaine.
Chloroprocaine The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Chloroprocaine.
Phenol The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Phenol.
Tetrodotoxin The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Tetrodotoxin.
Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Benzyl alcohol.
Capsaicin The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Capsaicin.
Etidocaine The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Etidocaine.
Articaine The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Articaine.
Tetracaine The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Tetracaine.
Propoxycaine The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Propoxycaine.
Pramocaine The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Pramocaine.
Butamben The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Butamben.
Butacaine The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Butacaine.
Oxetacaine The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Oxetacaine.
Ethyl chloride The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Ethyl chloride.
Butanilicaine The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Butanilicaine.
Metabutethamine The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Metabutethamine.
Quinisocaine The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Quinisocaine.
Voriconazole The serum concentration of Crenolanib can be increased when it is combined with Voriconazole.
Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Crenolanib.
Ambroxol The risk or severity of methemoglobinemia can be increased when Crenolanib is combined with Ambroxol.
Etrasimod The risk or severity of immunosuppression can be increased when Crenolanib is combined with Etrasimod.
Palopegteriparatide The therapeutic efficacy of Palopegteriparatide can be decreased when used in combination with Crenolanib.

Target Protein

Platelet-derived growth factor receptor alpha PDGFRA
Proto-oncogene tyrosine-protein kinase Src SRC

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul